1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Deals

Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed

French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases

 
• By Malcolm Spicer

After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.

• Source: Sanofi

Sanofi reports an historic step for the potential first US OTC switch of an erectile dysfunction drug while refusing even the slightest nod toward an imminent spin-out of its consumer business, a key driver in its 8.6% net sales growth for its latest quarter.

After cough/cold sales led the way in the first quarter at 118.2% growth for 17% overall consumer business growth to €1.33bn ($1.41bn), measured at a constant currency exchange rate (CER)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Urgo Makes Moves In Poland And Belgium

 
• By Tom Gallen

French consumer health player Urgo has added to its dietary supplements offering with separate deals in Poland and Belgium.

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

More from Business

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 
• By Malcolm Spicer

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.